Biosite Expands Distributor Network in the Physician Office Segment

SAN DIEGO, March 5  /PRNewswire-FirstCall/ -- Biosite Incorporated (NASDAQ:BSTE) today announced the addition of McKesson Corporation to its distributor network.  McKesson joins Physician Sales and Service (PSS), Henry Schein/Caligor and Fisher HealthCare Division of Thermo Fisher Scientific Company as distributors of Biosite's point-of-care diagnostic products to the physician office market.

"McKesson's knowledge and market leadership position in key states expands our sales efforts in primary care," said Kim Blickenstaff, Biosite's chairman and chief executive officer.  "The addition of McKesson to our physician office distribution network further strengthens our commitment to the primary care market and will allow us to provide more physicians with access to our product portfolio."

Biosite's leading product offering for physicians treating outpatients is the Triage(R) BNP Test, which aids in the diagnosis and assessment of heart failure and in the risk stratification of patients with acute coronary syndromes and/or heart failure.  The CLIA-waived blood test can be entirely performed in approximately 15-minute, using a small, portable meter.  Biosite offers a variety of other rapid tests for cardiovascular conditions, drug screening and infectious diseases.

For information about how to order Biosite products, please contact Biosite at (888) BIOSITE (246-7483), or email: .

About Biosite Incorporated

Biosite Incorporated is a leading bio-medical company commercializing proteomics discoveries for the advancement of medical diagnosis. The Company's products contribute to improvements in medical care by aiding physicians in the diagnosis of critical diseases and health conditions.  The Biosite(R) Triage(R) rapid diagnostic tests are used in more than 50 percent of U.S. hospitals and in more than 60 international markets.  Information on Biosite can be found at http://www.biosite.com/.

Except for the historical information presented herein, matters discussed in this press release are forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements.  Statements that are not historical facts, including but not limited to statements that are preceded by, followed by, or that include the words "will"; "believes"; "should"; "intends"; "anticipates"; "plans"; "expects"; "estimates"; or similar statements are forward-looking statements.  Forward looking statements include statements concerning McKesson's ability to expand our sales efforts in the primary care market and physician access to our product portfolio.  Risks and uncertainties include risks associated with McKesson's ability to sell our products to physician office laboratories, changing market conditions, the availability of competitive products, and the extent to which our products and products under development are successfully developed and gain market acceptance.  Other risks that should be considered include, risks associated with the introduction of competitive products from companies with greater capital and resources, contract disputes, patent conflicts, product recalls, manufacturing constraints, backlog, delays, or inefficiencies, shipment problems, seasonal customer demand, the timing of significant orders, changes in reimbursement policies, competitive pressures on average selling prices, changes in the mix of products sold, and the other risks detailed Biosite's most recent Annual Report on Form 10-K, and subsequent SEC filings.  The Company disclaims, however, any intent or obligation to update these forward-looking statements. Copies of Biosite's public disclosure filings are available from the investor relations department.

Biosite(R), Triage(R) and New Dimensions in Diagnosis(R) are registered trademarks of Biosite Incorporated.  The Company's logo is a trademark of Biosite Incorporated. 

DATASOURCE: Biosite Incorporated



CONTACT:  Nadine Padilla, Vice President, Corporate & Investor Relations

of Biosite Incorporated, [phone], 



Web site:  http://www.biosite.com/ 



Company News On-Call:  http://www.prnewswire.com/comp/116737.html 

Copyright